FDA approves Pylarify for diagnosis of advanced/recurrent forms of prostate cancer | THE "NEW" PROSTATE CANCER INFOLINK

FDA approves Pylarify for diagnosis of advanced/recurrent forms of prostate cancer | THE "NEW" PROSTATE CANCER INFOLINK: In ,a recent media release, Lantheus Holdings announced that the US Food and Drug Administration (FDA) had approved the imaging agent known as piflufolastat F 18 Injection (also known as Pylarify® …

prostatecancerinfolink.net

FDA approves Pylarify for diagnosis of advanced/recurrent forms of prostate cancer

2-3 minutes

Posted on May 31, 2021 by Sitemaster

In ,a recent media release, Lantheus Holdings announced that the US Food and Drug Administration (FDA) had approved the imaging agent known as piflufolastat F 18 Injection (also known as Pylarify® or more commonly just “PyL”) as a PSMA-based PET imaging agent for identification of prostate cancer.

This agent is actually approved for use in two types of patient: men suspected of having either metastatic or recurrent forms of prostate cancer — even if there is no sign of metastasis on a bone or normal CT scan.

There are now four imaging agents that can be used with PET or of PET/CT scans to identify forms of prostate cancer that may not be easily visible on standard types of scan:

  • The choline C-11 PET/CT scan, used primarily at the Mayo Clinic
  • The Axumin-based PET/CT scan, which is now widely available in the US
  • The gallium-68 PSMA-based PET scan, that is only available at a small number of academic centers and now
  • This newly approved Pylarify-based PET scan

The question now is going to be whether any one of these tests is significantly better than the other three in definable subtypes of patient. At present there is little to no information to show this with accuracy, but Prostate Cancer International profoundly hopes that relevant trials can be conducted to explore this question.

The use of PET scanning in the management of prostate cancer is expensive and restricted to a limited number of centers. It is NOT a technique liable to be available widely in community treatment settings. It will NOT be in the interest of patients if we cannot reach earlky consensus on the most appropriate use of the best of these tests in the right patients.

Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: , , , |

 

Comments

Post a Comment

Popular posts from this blog

A 10-Second Steam Blast: The New Weapon Against Prostate Cancer?

Image
Vanquish® Water Vapor Ablation System, Francis Medical Steams Out Prostate Cancer The Vanquish® Water Vapor Ablation System, developed by Francis Medical, Inc. , represents an innovative approach to treating prostate cancer using water vapor (steam) to ablate cancerous tissue. This minimally invasive technique aims to target and destroy prostate cancer cells while minimizing damage to surrounding healthy tissue, potentially reducing common side effects associated with traditional treatments like surgery and radiation, Mechanism of Action:  The Vanquish system utilizes the thermal energy stored in sterile water vapor to ablate cancerous prostate tissue. During the procedure, a catheter is inserted through the urethra into the prostate, delivering water vapor directly to the targeted tissue. As the vapor condenses back into liquid, it releases stored thermal energy, effectively destroying the cancerous cells. This method is designed to respect the prostate's natural boundaries, ...
Read more

Researchers develop low-cost device that detects cancer in an hour | ScienceDaily

Image
Summary Sanjay S. Timilsina , currently Lead Scientist, StataDx, a spinoff from Wyss Institute, former Postdoctoral Fellow at Harvard Medical School and the Wyss Institute at Harvard University, PhD from UTEP Department of Chemistry & Biochemistry, and XiuJun Li full Professor in the Department of Chemistry and Biochemistry and of Forensic Science, & Environmental Science and Engineering, at the University of Texas at El Paso (UTEP) have developed a new portable device for cancer detection that offers several advantages over traditional methods: Key Features: - Low cost (a few dollars per device, <8 cents per assay) - Provides results in about 1 hour (vs. 12-16 hours for traditional methods) - Approximately 10 times more sensitive than traditional methods - Portable and doesn't require specialized instruments - Can detect both CEA colorectal and PSA prostate cancer biomarkers - Uses a "paper-in-polymer-pond" structure to analyze blood samples How it works: - U...
Read more

Cancer patients and doctors team up to change how cancer drugs are tested | Fox News

Cancer patients and doctors team up to change how cancer drugs are tested | Fox News foxnews.com Associated Press For cancer patients, the harsh side effects of powerful drugs have long been the trade-off for living longer. Now, patients and doctors are questioning whether all that suffering is necessary. They’ve ignited a movement to radically change how new cancer drugs are tested, with the U.S. Food and Drug Administration urging drugmakers to do a better job at finding the lowest effective dose, even if it takes more time. Advances in treatment mean millions of people are surviving for years with incurable cancers. Jill Feldman, 54, of Deerfield, Illinois, has lived 15 years with lung cancer , thanks to that progress. Her parents both died of lung cancer months after their diagnoses. But her cancer drug causes joint pain, fatigue and mouth sores that m...
Read more